Emergent BioSolutions (NYSE:EBS) Updates FY 2021 Earnings Guidance


Share on StockTwits

Emergent BioSolutions (NYSE:EBS) issued an update on its FY 2021 earnings guidance on Tuesday morning. The company provided EPS guidance of – for the period. The company issued revenue guidance of $1.70 billion-$1.90 billion, compared to the consensus revenue estimate of $2 billion.

Several research firms recently issued reports on EBS. Guggenheim decreased their target price on shares of Emergent BioSolutions from $130.00 to $110.00 and set a buy rating on the stock in a research report on Wednesday, April 14th. Benchmark decreased their target price on Emergent BioSolutions from $150.00 to $120.00 and set a buy rating for the company in a research report on Friday. Chardan Capital reduced their price target on shares of Emergent BioSolutions from $112.00 to $92.00 and set a buy rating on the stock in a research report on Friday. Finally, Wells Fargo & Company lowered shares of Emergent BioSolutions from an overweight rating to an equal weight rating and set a $110.00 target price for the company. in a research note on Friday, January 8th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Emergent BioSolutions currently has a consensus rating of Buy and an average target price of $103.43.

EBS stock opened at $61.59 on Tuesday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.30 and a current ratio of 3.20. Emergent BioSolutions has a 1 year low of $60.70 and a 1 year high of $137.61. The stock’s fifty day moving average is $78.89 and its two-hundred day moving average is $92.24. The stock has a market capitalization of $3.30 billion, a price-to-earnings ratio of 19.80 and a beta of 1.26.

Emergent BioSolutions (NYSE:EBS) last posted its earnings results on Wednesday, April 28th. The biopharmaceutical company reported $1.53 EPS for the quarter, topping the consensus estimate of $0.97 by $0.56. Emergent BioSolutions had a net margin of 12.50% and a return on equity of 26.68%. As a group, analysts predict that Emergent BioSolutions will post 6.94 EPS for the current fiscal year.

In other Emergent BioSolutions news, Director Sue Bailey sold 8,168 shares of Emergent BioSolutions stock in a transaction on Thursday, March 4th. The stock was sold at an average price of $92.37, for a total transaction of $754,478.16. Following the sale, the director now owns 24,427 shares of the company’s stock, valued at approximately $2,256,321.99. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 14.10% of the stock is owned by company insiders.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.

Further Reading: How to start trading in the forex market?

Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.